Weekly Sales Enablement Briefing — Cosentyx

Week ending August 16, 2026

1. What’s coming up in conversations this week

• “Cosentyx vs. Taltz— which is better?” AI answers repeatedly recommend a neutral, patient-fit discussion: efficacy, dosing, injection experience, comorbidities, coverage, and patient priorities.
• Effectiveness and safety versus older biologics. Patients may ask how Cosentyx compares with Humira for psoriasis or whether it is “stronger” than Enbrel. AI generally frames these as different mechanisms and response patterns, not a universal potency ranking.
• Practical switching and access questions. Switching from another IL-17 biologic is being framed around prior authorization, formulary preference, onset expectations, and tolerability—not necessarily a major mechanistic change.
• Safety and special populations. Prescribers and patients are asking about active infection, TB screening, inflammatory bowel disease, pregnancy/lactation, live vaccines, and renal/hepatic impairment.
• Dosing and administration. Questions include the plaque-psoriasis loading schedule, maintenance dosing, pen versus syringe, refrigeration, and injection steps.

2. Competitive talking points

Taltz is the leading comparison this week (10 mentions), followed by Humira and Stelara (9 each), then Enbrel (8).

AI commonly describes Cosentyx and Taltz as “both reasonable” IL-17 options and recommends matching treatment to patient priorities. Reps should expect questions about speed, dosing, tolerability, comorbidities, and coverage. AI-generated language such as “best,” “superior,” and “stronger” appears in Taltz comparisons; recognize this as circulating answer language, not verified messaging.

For Humira, AI contrasts IL-17A versus TNF-alpha and discusses differences in response timing and safety considerations. For Stelara, it highlights IL-17A versus IL-12/23 and dosing frequency. For Enbrel, the repeated coaching is to avoid a “stronger/weaker” frame and focus on mechanism, evidence, regimen, and individual treatment goals.

3. Questions and objections to be ready for

• “Can I start or continue Cosentyx with an active infection?” Answers vary in how strongly they describe holding treatment; direct reps to the current prescribing information and the prescriber’s clinical judgment.
• “What boxed warning or major infection warning applies?” AI responses conflict—most say no U.S. boxed warning, while one says there is one. Reps should use the current approved PI, not an AI summary.
• “For plaque psoriasis, is loading once weekly for four weeks or five doses?” This was a recurring dosing question, and answer variants disagree. Keep the current indication-specific dosing reference immediately available.
• “Can the pharmacy substitute a generic or biosimilar?” Be ready to distinguish a traditional generic from any applicable biosimilar or alternative biologic, subject to local approval, prescribing, and pharmacy rules.

4. What’s changed since last week

The question mix is unchanged, but volume fell from 140 to 120 responses and inconsistency flags declined from 27 to 24. Safety themes remain steady-state priorities. Tremfya mentions increased from 1 to 2; other named competitors declined.

5. Recommended actions

1. Add a short Taltz comparison opener emphasizing patient fit and neutral language.
2. Refresh the rep quick-reference for current PI-based infection, IBD, pregnancy, vaccine, and boxed-warning wording.
3. Verify and circulate one indication-specific dosing card, given conflicting AI loading schedules.
4. Add a generic-versus-biosimilar response to access-prep materials.
5. No broad competitive reset this week; prioritize call-ready clarification over new strategy.